HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hutton, J.T. Articles by Morris, J.L. Search for Related Content PubMed PubMed Citation Articles by Hutton, J.T. Articles by Morris, J.L.

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

From the Neurology Research and Education Center (Dr. Hutton and J.L. Morris), St. Mary of the Plains Hospital, Lubbock, TX; the Department of Neurology (Drs. Koller and Pahwa), University of Kansas Medical Center, Kansas City, KS; the Department of Neurology (Dr. Ahlskog), Mayo Clinic, Rochester, MN; the Department of Neurology (Drs. Hurtig and Stern), The Graduate Hospital, Philadelphia, PA; The Marshfield Clinic (Dr. Hiner), Marshfield, WI; Barrow Neurological Institute (Dr. Lieberman), Phoenix, AZ; the Department of Neurology (Dr. Pfeiffer), University of Tennessee, Memphis, TN; the Department of Neurology (Dr. Rodnitzky), University of Iowa Hospitals, Iowa City, IA: the Department of Neurology (Dr. Waters), University of Southern California, Los Angeles, CA; and Mayo Clinic Scottsdale (Drs. Muenter and Adler), Scottsdale, AZ.
Supported by a grant from Pharmacia Inc.
Received May 19, 1995. Accepted in final form August 17, 1995.
Address correspondence and reprint requests to Dr Hutton, Neurology Research and Education Center, St. Mary of the Plains Hospital, 4102 24th St., Suite 500, Lubbock, TX 79410.

Cabergoline is a dopaminergic agonist relatively specific for the D sub 2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p equals 0.032) and Motor Examination (p equals 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p less than 0.001). The amount of time in the ``on'' state increased more in the cabergoline group (p equals 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

NEUROLOGY 1996;46: 1062-1065

This article has been cited by other articles:

				M. P. Gillam, S. Middler, D. J. Freed, and M. E. Molitch The Novel Use of Very High Doses of Cabergoline and a Combination of Testosterone and an Aromatase Inhibitor in the Treatment of a Giant Prolactinoma J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4447 - 4451. [Abstract] [Full Text] [PDF]

				M. Wittstock, R. Benecke, and D. Dressler Cabergoline can increase penile erections and libido Neurology, March 12, 2002; 58(5): 831 - 831. [Full Text] [PDF]

				Developments in the treatment of Parkinson's disease DTB, May 1, 1999; 37(5): 36 - 40. [Abstract] [Full Text] [PDF]